ReviewChest2026
Applying Precision Medicine to the Heterogeneity of Asthma Attacks.
Review in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Type 2-low Asthma: Epidemiology, Multiomics, and Emerging Therapies.Current allergy and asthma reports · 2026Review
- [Microbiological Characterization of Exacerbations in Severe Asthma and Their Impact on Therapeutic Decision-Making].Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
topic importanceThe standard of care for management of asthma attacks has remained unchanged for 70 years, relying on a symptom-based, severity-stratified approach. Severe asthma attacks are defined by a worsening of asthma requiring oral corticosteroid (OCS) treatment for unresolved symptoms for at least 48 hours, decreased lung function, or both. The 1-size-fits-all strategy with OCS treatment overlooks the biological mechanisms driving attacks and may lead to suboptimal outcomes. Importantly, OCS-related toxicities lead to significant morbidity, and cumulative OCS use has been associated with increased mortality. Antibiotics, often used indiscriminately, also increase adverse events and antimicrobial resistance. REVIEW
findingsRecent studies have highlighted the heterogeneity of asthma attacks across clinical, etiologic, and therapeutic dimensions. Biomarker-informed assessments using blood eosinophils, exhaled nitric oxide (Feno), and point-of-care microbial molecular testing have improved the evaluation of attacks. Observational studies and trials have explored biomarker-guided management to reduce OCS and antibiotic use, potentially improving outcomes. Distinct inflammatory and OCS response profiles were identified in patients receiving biologics, emphasizing the complexity of attacks and the importance of residual (untreated) type 2 inflammatory pathways. Studies of the airway microbiome revealed that microbial dysbiosis is associated with clinical and inflammatory clusters. SUMMARY: Asthma attacks are complex episodes with diverse causes, endotypes, and phenotypes. Emerging evidence supports incorporating biomarkers (blood eosinophils, Feno, and microbial testing) into clinical assessment to refine management. Recent evidence expands our understanding of exacerbation mechanisms, highlighting the need for tailored management strategies. Recognizing asthma heterogeneity could shift care toward precision medicine, reducing OCS reliance and improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.